RESULTS FROM 1 TO 4 OF 4

2021, Articolo in rivista, ENG

A multivariate analysis of Multiple Myeloma subtype plasma cells

Bonsignore, Martina; Trusso, Sebastiano; De Pasquale, Claudia; Ferlazzo, Guido; Allegra, Alessandro; Innao, Vanessa; Musolino, Caterina; Franco, Domenico; De Plano, Laura Maria; Guglielmino, Salvatore Pietro Paolo; Neri, Fortunato; Fazio, Enza

Trusted methods for identifying different Multiple Myeloma (MM) cells and their biological diversity due to their immunophenotypic variety are often little detailed and difficult to find in literature. In this work, we show that micro-Raman spectroscopy can be used to highlight if there is a certain degree of distinction or correlation between the MM subtype plasmacells in relation to the cluster of differentiation (CD45 +/CD38+/CD138-) and (CD45-/CD38+/CD138+). After taking samples from the bone marrow of patients with Multiple Myeloma, the PCs were sorted by flow cytometry, selecting the most common CD of the disease, i.e. CD 45, CD38 and CD138. Some spectral differences are observed comparing the Raman spectra of the two set of samples investigated. To better define in which spectral regions there are greater differences and, therefore, to which biological contributions the changes refers, we also explored the principal component analysis (PCA) of the collected Raman data. The spectral variations between the different sorted cells have been highlighted by plotting loading vectors PC1 and PC2, which shows a net differentiation between the two set of cells. Ultimately, the differences shown by PCA have been associated with the spectral variations observed and explained in terms of changes of proteins and lipid contributions. Thus, the differentiation of Multiple Myeloma subtype plasma cells by confocal micro-Raman spectroscopy can be proposed as a diagnostic tool in the speeding up of cell identification, assessing the intracellular biochemical changes that take place in cancer cells. (c) 2021 Published by Elsevier B.V.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy (Print) 258

DOI: 10.1016/j.saa.2021.119813

2020, Articolo in rivista, ENG

Changes in serum interleukin-8 and sRAGE levels in multiple myeloma patients

Alessandro Allegra; Elisabetta Pace ; Gennaro Tartarisco ; Vanessa Innao ; Eleonora Di Salvo ; Andrea Gaetano Allegra; Maria Ferraro ; Caterina Musolino ; Sebastiano Gangemi

Background/Aim: Although numerous cytokines influence proliferation and progression of multiple myeloma (MM), a relevant action in the onset of the disease also seems to be played by the oxidative state. Patients and Methods: In the present study we evaluated the concentrations of interleukin-8 (IL-8) and soluble receptor of advanced glycation end products (sRAGE) in patients with MM, assessing the existing variations with respect to a control group and the possible existence of correlations between these molecules and the biological variables or the presence of a correlation between IL-8 and sRAGE. The study was conducted on 33 patients affected by MM compared to 39 healthy subjects. Results: IL-8 and sRAGE levels were significantly higher in MM patients compared to healthy subjects. sRAGE and IL-8 evidence no significant linear correlation. Furthermore, IL-8 was significantly increased in both sexes, but we found a slight variation for females compared to males. Conclusion: IL-8 could play an important role in the onset of MM and the progression of bone disease, while the increased sRAGE values would seem to have a protective action in MM patients. Further studies on animal models may clarify the real impact of introducing modulation of IL-8 and sRAGE levels.

Anticancer research 40, pp. 1443–1449

DOI: 10.21873/anticanres.14086

2017, Articolo in rivista, ENG

p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells

Soriani, Alessandra; Borrelli, Cristiana; Ricci, Biancamaria; Molfetta, Rosa; Zingoni, Alessandra; Fionda, Cinzia; Carnevale, Silvia; Abruzzese, Maria Pia; Petrucci, Maria Teresa; Ricciardi, Maria Rosaria; La Regina, Giuseppe; Di Cesare, Erica; Lavia, Patrizia; Silvestri, Romano; Paolini, Rossella; Cippitelli, Marco; Santoni, Angela

The mechanisms that regulate the expression of the NKG2D and DNAM-1 activating ligands are only partially known, but it is now widely established that their expression is finely regulated at transcriptional, post-transcriptional and post-translational level, and involve numerous stress pathways depending on the type of ligand, stressor, and cell context. We show that treatment of Multiple Myeloma (MM) cells with sub-lethal doses of Vincristine (VCR), an anticancer drug that inhibits the assembly of microtubules, stimulates the expression of NKG2D and DNAM-1 activating ligands, rendering these cells more susceptible to NK cell-mediated killing. Herein, we focused our attention on the identification of the signaling pathways leading to de novo surface expression of ULBP-1, and to MICA and PVR upregulation on VCR-treated MM cells, both at protein and mRNA levels. We found that p38MAPK differentially regulates drug-dependent ligand upregulation at transcriptional and post-transcriptional level. More specifically, we observed that ULBP-1 expression is attributable to both increased transcriptional activity mediated by ATM-dependent p53 activation, and enhanced mRNA stability; while the p38-activated E2F1 transcription factor regulates MICA and PVR mRNA expression. All together, our findings reveal a previously unrecognized activity of VCR as anticancer agent, and indicate that in addition to its established ability to arrest cell growth, VCR can also modulate the expression of NKG2D and DNAM-1 activating ligand on tumor cells and thus promoting NK cell-mediated immunosurveillance.

ONCOIMMUNOLOGY 6 (1)

DOI: 10.1080/2162402X.2016.1264564

2014, Articolo in rivista, ENG

Percutaneous vertebroplasty for pain management in patients with multiple myeloma: Is radiofrequency ablation necessary?

Orgera G.; Krokidis M.; Matteoli M.; Varano G.M.; La Verde G.; David V.; Rossi M.

Purpose: This study was designed to investigate the added role of radiofrequency ablation (RFA) to vertebroplasty on the pain management of patients with multiple myeloma (MM). Methods: Thirty-six patients (51-82 years) with vertebral localization of MM were randomly divided into two groups: 18 patients (group A) who underwent RFA and then vertebroplasty, and 18 patients (group B) who underwent only vertebroplasty. Primary endpoints were technical success and pain relief score rate measured by the visual analogue pain scores (VAS) and Roland-Morris Questionnaire (RMQ); secondary endpoint was the amount of administered analgesia. Survival and complications were compared. Results: Technical success was 100 % in both groups. The VAS score (at 24 h and 6 weeks postprocedure) decreased in equal manner for both groups from a mean of 9.1-3.4 and 2.0 for group A and from a mean of 9.3-3.0 and 2.3 for group B; RMQ mean score was 19.8 for group A and 19.9 for group B and decreased to a mean of 9.6 and 8.2 for group A and 9.5 and 8.7 for group B. The amount of medication was equally decreased in the two groups. No statistically significant difference was noted. No major complication occurred and two patients died from other causes. Conclusions: The use of percutaneous vertebroplasty alone appears to be effective for the pain management of the patients with vertebral involvement of multiple myeloma. The use of RFA that includes cost and time does not offer any clear added benefit on the midterm pain management of such patients. © 2013 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Cardiovascular and interventional radiology (Print) 37 (1), pp. 203–210

DOI: 10.1007/s00270-013-0624-0

InstituteSelected 0/3
    IBPM, Istituto di biologia e patologia molecolari (1)
    IN, Istituto di neuroscienze (1)
    IRIB, Istituto per la Ricerca e l'Innovazione Biomedica (1)
AuthorSelected 0/6
    Ferraro Maria (1)
    Lavia Patrizia (1)
    Matteoli Michela (1)
    Pace Elisabetta (1)
    Tartarisco Gennaro (1)
    Trusso Sebastiano (1)
TypeSelected 0/1
    Articolo in rivista (4)
Research programSelected 0/1
    ME.P02.007.001, Farmacologia Cellulare e Molecolare delle Cellule Nervose (1)
EU Funding ProgramSelected 0/0
No values ​​available
EU ProjectSelected 0/0
No values ​​available
YearSelected 0/4
    2014 (1)
    2017 (1)
    2020 (1)
    2021 (1)
LanguageSelected 0/1
    Inglese (4)
Keyword

Multiple Myeloma

RESULTS FROM 1 TO 4 OF 4